Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $170.11 USD
Change Today -2.82 / -1.63%
Volume 578.6K
UTHR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

united therapeutics corp (UTHR) Snapshot

Open
$173.60
Previous Close
$172.93
Day High
$174.41
Day Low
$168.50
52 Week High
04/16/15 - $190.29
52 Week Low
08/7/14 - $86.04
Market Cap
7.9B
Average Volume 10 Days
643.1K
EPS TTM
$3.38
Shares Outstanding
46.2M
EX-Date
--
P/E TM
50.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for UNITED THERAPEUTICS CORP (UTHR)

united therapeutics corp (UTHR) Related Businessweek News

View More BusinessWeek News

united therapeutics corp (UTHR) Details

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

740 Employees
Last Reported Date: 02/24/15
Founded in 1996

united therapeutics corp (UTHR) Top Compensated Officers

Founder, Chairman and Co-Chief Executive Offi...
Total Annual Compensation: $1.0M
Co-Chief Executive Officer, President and Dir...
Total Annual Compensation: $840.4K
Executive Vice President of Strategic Plannin...
Total Annual Compensation: $731.0K
Compensation as of Fiscal Year 2014.

united therapeutics corp (UTHR) Key Developments

United Therapeutics Corporation Appoints Dean Judy D. Olian as Member of the Board

United Therapeutics Corporation announced that on June 26, 2015, the Board of Directors of the company appointed Dean Judy D. Olian of the UCLA Anderson School of Management to serve as a member of the Board. Dean Olian will serve as a Class II director, and her term will expire at the company's 2016 annual meeting of shareholders.

United Therapeutics Corp. Plans to Expand Silver Spring Campus

United Therapeutics Corp. announced that it is planning a major expansion of its Silver Spring campus with plans to hire about 100 employees in the next three to six years. The company wants to develop a six-story building at the southwest corner of Spring Street and Colesville Road connecting to its existing corporate presence in the immediate area. The 121,724-square-foot building, to include new office, lab and retail space, would be developed on the site of what is now a three-story parking garage owned by Montgomery County that is under contract for sale to United Therapeutics. The development site is in the same block as United Therapeutics' headquarters at 1040 Spring St. The new facility is expected to house 100 people in new divisions United Therapeutics is planning to create, though those details are still being worked out. United Therapeutics now employs about 175 people. United Therapeutics has not sought incentives from the county or state to help support its growth.

Mayo Clinic and United Therapeutics Collaborate on Lung Restoration Center

Mayo Clinic in Jacksonville and United Therapeutics Corporation announced a collaboration to build and operate a lung restoration center on the Mayo campus. The goal is to significantly increase the volume of lungs for transplantation by preserving and restoring selected marginal donor lungs, making them viable for transplantation. The restored lungs will be made available to patients at Mayo Clinic and other transplant centers throughout the United States. Construction of the center is expected to be completed in late 2017. Financial details of the agreement were not disclosed.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTHR:US $170.11 USD -2.82

UTHR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.138.30 CHF +0.80
Alexion Pharmaceuticals Inc $185.22 USD +1.36
Celanese Corp $73.72 USD +1.72
Nippon Shinyaku Co Ltd ¥4,085 JPY -35.00
Vertex Pharmaceuticals Inc $131.26 USD +5.07
View Industry Companies
 

Industry Analysis

UTHR

Industry Average

Valuation UTHR Industry Range
Price/Earnings 48.1x
Price/Sales 6.1x
Price/Book 7.3x
Price/Cash Flow 43.0x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.